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Human T-cell leukemia virus type 1 (HTLV-1) causes
both neoplastic and inflammatory diseases: adult T-cell
leukemia (ATL) and HTLV-1-associated myelopathy/
tropical spastic paraparesis (HAM/TSP). Since these dis-
abling and/or life threatening diseases are not yet cur-
able, it is important to prevent new infections. In this
study, we have established a simple humanized mouse
model of HTLV-1 infection for evaluating therapeutic
and immunomodulatory interventions. Using this model,
we tested the effect of HTLV-1 specific neutralizing
antibodies. HTLV-1-negative normal human peripheral
blood mononuclear cells (PBMCs) were transplanted
directly into the spleens of severely immunodeficient
mice (NOD/SCID/gCnull: NOG) together with the mito-
mycin-treated HTLV-1 producing T cells (ILT-M1).
Before (one hour) and after (24 hours) transplantation
of human PBMCs, monoclonal antibodies against
HTLV-1 as well as human IgG isolated from both
HTLV-1 infected and non-infected individuals were
inoculated intraperitonealy. On day 14, human PBMCs
were isolated from mouse spleen, and tested for HTLV-
1 infection by real time PCR and flow cytometry. Similar
to the naturally HTLV-1 infected PBMCs, both CD4+
and CD8+ T cells isolated from untreated or isotype
antibody treated mice were found to be HTLV-1
infected, and the CD8+ T cells harbored HTLV-1 to a
lesser extent. Also, HTLV-1 Tax expression was nega-
tive in isolated human PBMCs but became positive after
16 hours of culture. Although non-neutralizing mono-
clonal antibodies to gp46, monoclonal antibody to gag
p19, and normal human IgG did not block the infection,
neutralizing monoclonal antibody to gp46 and human
anti-HTLV-1 IgG completely blocked the infection. Our
findings provide a new strategy for preventing initial
HTLV-1 infection and blocking further spread in vivo.
The potential mechanisms involved in the antibody
effect will also be discussed.
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